These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 27080498)

  • 21. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
    Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
    Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
    Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P; Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
    J Clin Oncol; 2002 Jun; 20(12):2783-8. PubMed ID: 12065554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
    Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
    Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
    Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
    Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
    Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
    Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
    Dartigeas C; Van Den Neste E; Léger J; Maisonneuve H; Berthou C; Dilhuydy MS; De Guibert S; Leprêtre S; Béné MC; Nguyen-Khac F; Letestu R; Cymbalista F; Rodon P; Aurran-Schleinitz T; Vilque JP; Tournilhac O; Mahé B; Laribi K; Michallet AS; Delmer A; Feugier P; Lévy V; Delépine R; Colombat P; Leblond V; ;
    Lancet Haematol; 2018 Feb; 5(2):e82-e94. PubMed ID: 29275118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
    Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
    J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
    Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
    Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
    Borchmann P; Goergen H; Kobe C; Lohri A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Hüttmann A; Dierlamm J; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Schmitz N; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Kuhnert G; Diehl V; Dietlein M; Engert A
    Lancet; 2017 Dec; 390(10114):2790-2802. PubMed ID: 29061295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-intensity therapy in adults with Burkitt's lymphoma.
    Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
    N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
    Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
    Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.